British National Formulary : BNF 90, September 2025 – March 2026

The first choice for concise medicines information

Practical and evidence based, British National Formulary (BNF) is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes.

Practical and evidence-based, BNF is an integral part of the UK’s healthcare infrastructure and relied on by health professionals who prescribe, dispense, and administer medicines globally.  Containing guidance on best practice in prescribing, as well as legal and ethical considerations, BNF supports safe and effective decision-making at the point of care.

Extensive content updates in the BNF 90 edition include:

New monographs for:

• Agamree® [vamorolone] for treatment of Duchenne muscular dystrophy
• Anzupgo® [delgocitinib] for treatment of moderate-to-severe hand eczema
• Briumvi® [ublituximab] for treatment of multiple sclerosis
• Duvyzat® [givinostat] for treatment of Duchenne muscular dystrophy
• Joenja® [leniolisib] for treatment of activated phosphoinositide 3-kinase delta syndrome
• Kisunla® [donanemab] for treatment of mild cognitive impairment or mild dementia in Alzheimer’s disease
• Lunivia® [eszopiclone] for short-term treatment of insomnia
• Vafseo® [vadadustat] for treatment of symptomatic anaemia associated with chronic kidney disease in patients on chronic maintenance dialysis
• Winlevi® [clascoterone] for treatment of acne vulgaris
• Yorvipath® [palopegteriparatide] for treatment of chronic hypoparathyroidism

MHRA advice on:

• Fezolinetant: risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment
• GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation
• Prolonged-release opioids: removal of indication for relief of post-operative pain
• Sodium valproate and Valproic acid: new advice for male patients already taking these

Other significant changes include updated guidance on:

• Amphotericin B: review of indications and dose for liposomal preparations, as well as updates to directions for administration, breast-feeding, pregnancy, cautions, and monitoring advice
• Apixaban: update to structure of dosing for prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor
• Asthma, chronic: updated guidance on management
• Bempedoic acid: new indication and dose for established or at high-risk of atherosclerotic cardiovascular disease
• Bimekizumab: new indication and dose for hidradenitis suppurativa
• Budesonide with formoterol (DuoResp Spiromax® 160 micrograms/4.5 micrograms, and Fobumix® 160/4.5 Easyhaler): new indication and dose for mild asthma, reliever therapy
• Cardiovascular disease risk assessment and prevention: updated guidance
• Chloroquine: updated pregnancy and breast-feeding advice when used for rheumatic disease
• Contraceptives, hormonal: inclusion of guidance for use of combined oral contraceptives for preventive treatment of ovarian cancer in at-risk females
• Dupilumab: new indication and dose for chronic obstructive pulmonary disease
• Emtricitabine with tenofovir alafenamide: new indication and dose for pre-exposure prophylaxis of HIV-1 infection
• Hydroxychloroquine sulfate: updated pregnancy and breast-feeding advice
• Malaria prophylaxis: updated guidance
• Naltrexone hydrochloride: new indication and dose for gambling-related harm
• Pneumococcal polysaccharide conjugate vaccine (adsorbed): name change of Apexxnar® to Prevenar 20®
• Sepsis: updated guidance on management
• Smoking cessation: updated drug treatment guidance
• Sympathomimetics: updated guidance for septic shock
• Tuberculosis: updated guidance for multi-drug resistant tuberculosis
• Wegovy® (semaglutide): new indication and dose for cardiovascular risk reduction

BNF is published jointly by BMJ Group and Pharmaceutical Press.